Compare BioNTech SE - ADR (BNTX) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Emerson Electric Co. — how do they compare? BioNTech SE - ADR trades at $92.99 (market cap $23.31B), while Emerson Electric Co. trades at $163.54 (market cap $91.69B). The key difference: Emerson Electric Co. is far larger — about 3.9× BioNTech SE - ADR's market cap, and Emerson Electric Co. pays a 1.35% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | EMR | |
|---|---|---|
Market Cap | $23.31B | $91.69B |
Sector | Health | Industrials |
52-Week High | $119.34 | $164.38 |
52-Week Low | $83.89 | $123.30 |
Enterprise Value | $6.60B | $102.77B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Emerson Electric (EMR) trades at $158.69, up 0.27% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.71 exceeding expectations, supported by 7% revenue growth and expanding margins. Recent acquisition of Glue Inc. enhances AI capabilities while dividend payments provide shareholder returns.
Outlook remains positive with raised 2026 guidance and $171.33 consensus price target offering 8% upside. Key risks include valuation at 36x P/E and cyclical exposure to industrial markets. Institutional support remains strong with 53.7% buy ratings, though RSI levels suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
